Health Care · Pharmaceutical Preparations

ELDN Eledon Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 140428188 filings
Russell 2000

ELDN at a glance

Eledon Pharmaceuticals, Inc. (ELDN, SEC CIK 1404281) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Eledon Pharmaceuticals, Inc. (ELDN) shares worth $46.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$46.7M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly disclosed going-concern risk: $69.7 million liquidity does not fund operations for at least twelve months
  • Clinical-development risk: Phase 3 kidney-transplant trial and islet-cell program require substantial additional financing
  • Regulatory risk: 2025 Trump executive orders may alter FDA rules and delay approvals
  • Manufacturing risk: no redundant supply arrangements for custom drug-production materials
  • Competitive risk: Vertex and other larger companies developing immune-evasive islet-cell therapies

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved products or product sales
  • Operating margin not meaningful, operating loss $21.7M vs $19.1M YoY
  • R&D expenses $17.8M, up $2.8M YoY, driven by $5.1M higher manufacturing costs
  • Cash, equivalents and short-term investments $69.7M, operating cash use $64.3M for nine months
  • Phase 3 LEGACY planned for late 2026, additional financing required, substantial doubt about going concern

AI summary of the ELDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Eledon’s quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s quarterly financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 2026 revenue-free biotech posted a $21.0M operating loss excluding warrant revaluation, highlighting continued cash burn ahead of Phase 3
  • Cash, equivalents and short-term investments $69.7M, funding operations into Q2 2027 but likely requiring additional financing afterward
Filed Aug 13, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA alignment supports global Phase 3 kidney-transplant trial, targeting approximately 600 patients and initiation in late 2026
  • BESTOW data showed eGFR approximately 12 mL/min/1.73 m² higher at 18 months versus tacrolimus, with p<0.05

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Eledon Pharmaceuticals’ results for quarter ended June 30, 2026
  • Investors should review Exhibit 99.1 for financial results, operating updates and management commentary
Filed Jun 22, 2026Full analysis →

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Stockholders approved a charter amendment at the June 18, 2026 Annual Meeting
  • Amendment details are incomplete in the provided filing excerpt, limiting assessment of shareholder-rights impact

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Three Class III directors elected through 2029, preserving board continuity
  • Authorized common shares increased 50%, from 300 million to 450 million

AI summaries of ELDN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ELDN

Don't miss the next ELDN filing

  • Alerts as it files. A push when ELDN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ELDN, by share count.
  • Ask anything. An AI agent that reads every ELDN filing and answers with sources.

ELDN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gros David-Alexandre CAJul 31, 2026-
Gros David-Alexandre CFJul 31, 2026$3.38
Perrin StevenAJul 31, 2026-
Perrin StevenFJul 31, 2026$3.38
Lee JuneMJan 10, 2026-
Lee JuneMJan 10, 2026-
Hillson JanMJan 10, 2026-
Hillson JanMJan 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$43.0M--
Net Income-$40.3M-$36.2M-$45.6M
Balance Sheet
Total Assets$89.1M$177.4M$169.0M
Equity$83.4M$118.1M$81.1M
ROE-48.3%-30.6%-56.3%
Per Share
EPS$-1.64$-0.75$-0.52
Cash Flow
Operating CF-$39.5M-$47.3M-$62.3M

Source: XBRL data in Eledon Pharmaceuticals, Inc. (ELDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ELDN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ELDN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$46.7M
Q2 202625$71.8M
Q1 202621$36.3M
Q4 202521$15.3M
Q3 202518$23.3M
Q2 202519$24.4M
Q1 202511$16.9M
Q4 20248$15.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ELDN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Aug 4, 2026--
4Aug 4, 2026--
SC 13GJul 31, 2026-
8-KJun 22, 2026Analysis-
8-KMay 13, 2026Analysis
10-QMay 13, 2026Analysis
SC 13GApr 27, 2026-
8-KMar 19, 2026Analysis-
10-KMar 19, 2026-
4Jan 16, 2026-
4Jan 16, 2026-
4Jan 16, 2026-
4Jan 16, 2026-
4Jan 16, 2026-
4Jan 16, 2026-
8-KJan 2, 2026-
SC 13GNov 24, 2025-
10-QNov 14, 2025Analysis
10-QAug 14, 2025-
SC 13GJul 29, 2025-
SC 13GJul 17, 2025-

Related Health Care companies

All Health Care →

ELDN SEC filings: frequently asked questions

Which institutions hold ELDN stock?

As of September 30, 2026, the largest Eledon Pharmaceuticals, Inc. (ELDN) holders among the 13F filers tracked by SignalX were BlackRock ($16.8 million), Vanguard Capital Management LLC ($8.6 million), Goldman Sachs Group ($6.5 million), State Street Corp ($4.1 million), Millennium Management ($2.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ELDN report in its latest 8-K?

Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Eledon’s quarter ended September 30, 2026.

What are the latest ELDN SEC filings?

Eledon Pharmaceuticals, Inc. (ELDN) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 4, 2026.

What is ELDN's SEC CIK number?

Eledon Pharmaceuticals, Inc. (ELDN)'s SEC Central Index Key (CIK) is 1404281. EDGAR lists every ELDN filing under that number.

Ask anything about ELDN

The research agent reads ELDN's filings, financials, insider trades and 13F holders, then answers with sources.